WuXi XDC Cayman Inc. (HKG:2268)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 92.51B +18.8% |
| Revenue (ttm) | 8.02B +36.5% |
| Net Income | 1.79B +17.1% |
| EPS | 1.33 +12.8% |
| Shares Out | 1.27B |
| PE Ratio | 54.99 |
| Forward PE | 33.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,471,034 |
| Open | 68.60 |
| Previous Close | 73.05 |
| Day's Range | 68.60 - 72.40 |
| 52-Week Range | 43.50 - 85.50 |
| Beta | -0.76 |
| Analysts | Strong Buy |
| Price Target | 92.09 (+27.73%) |
| Earnings Date | Aug 24, 2026 |
About WuXi XDC Cayman
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, m... [Read more]
Financial Performance
In 2025, WuXi XDC Cayman's revenue was 5.94 billion, an increase of 46.69% compared to the previous year's 4.05 billion. Earnings were 1.48 billion, an increase of 38.41%.
Financial numbers in CNY Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for 2268 stock is "Strong Buy." The 12-month stock price target is $92.09, which is an increase of 27.73% from the latest price.
News
WuXi XDC Cayman Earnings Call Transcript: H1 2026
Revenue grew 37% year-over-year to CNY 3.7 billion, with gross margin rising to 37% and backlog exceeding $2 billion. Integration of BioDlink and Singapore site launch enhanced global capacity, while innovation and commercial orders drive future growth.
WuXi XDC Cayman Earnings release: H1 2026
WuXi XDC Cayman released its H1 2026 earnings on August 25, 2026, summarizing the period's financial results.
WuXi XDC Cayman Slides: H1 2026
WuXi XDC Cayman has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 25, 2026.
Akari Therapeutics Announces Strategic Partnership With WuXi XDC
(RTTNews) - Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody-drug conjugates (ADCs) with novel RNA splicing modulating payloads, announced a strategic part...
WuXi XDC Cayman Earnings Call Transcript: H2 2025
2025 saw record revenue and profit growth, a surge in project signings, and a backlog exceeding $1.5 billion. Strategic acquisitions and capacity expansions position the company for 30%-35% CAGR, with commercial manufacturing revenue set to rise in coming years.
WuXi XDC Cayman Earnings release: H2 2025
WuXi XDC Cayman released its H2 2025 earnings on March 24, 2026, summarizing the period's financial results.
WuXi XDC Cayman Slides: H2 2025
WuXi XDC Cayman has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 24, 2026.
WuXi XDC Cayman Annual report: H2 2025
WuXi XDC Cayman has published its H2 2025 annual report on March 24, 2026.
US reshoring drive casts shadow over China’s contract drug makers: analyst
Chinese contract drug makers – including WuXi AppTec, WuXi Biologics and WuXi XDC – face a less certain long-term revenue outlook as US pharmaceutical companies bring production in-house and reconfigu...